Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
Total Valuation
Janux Therapeutics Inc has a market cap or net worth of $2.09B. The enterprise value is $549.53M.
Market Cap$2.09B
Enterprise Value$549.53M
Share Statistics
Janux Therapeutics Inc has 60,147,808 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding60,147,808
Owned by Insiders24.47%
Owned by Institutions2.93%
Financial Efficiency
Janux Therapeutics Inc’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -9.45%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-9.45%
Return on Capital Employed (ROCE)-0.09
Revenue Per Employee116.35K
Profits Per Employee-758.18K
Employee Count91
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Janux Therapeutics Inc is ―. Janux Therapeutics Inc’s PEG ratio is 13.76.
PE Ratio―
PS Ratio271.80
PB Ratio2.81
Price to Fair Value2.81
Price to FCF-65.15
Price to Operating Cash Flow-24.19
PEG Ratio13.76
Income Statement
In the last 12 months, Janux Therapeutics Inc had revenue of 10.59M and earned -68.99M in profits. Earnings per share was -1.28.
Revenue10.59M
Gross Profit8.53M
Operating Income-98.85M
Pretax Income-68.99M
Net Income-68.99M
EBITDA-96.79M
Earnings Per Share (EPS)-1.28
Cash Flow
In the last 12 months, operating cash flow was -70.42M and capital expenditures -979.00K, giving a free cash flow of -71.40M billion.
Operating Cash Flow-70.42M
Free Cash Flow-71.40M
Free Cash Flow per Share-1.19
Dividends & Yields
Janux Therapeutics Inc pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change-13.66%
50-Day Moving Average26.66
200-Day Moving Average26.88
Relative Strength Index (RSI)71.51
Average Volume (3m)1.15M
Important Dates
Janux Therapeutics Inc upcoming earnings date is Mar 6, 2026, After Close (Confirmed).
Last Earnings DateNov 6, 2025
Next Earnings DateMar 6, 2026
Ex-Dividend Date―
Financial Position
Janux Therapeutics Inc as a current ratio of 59.21, with Debt / Equity ratio of 2.32%
Current Ratio59.21
Quick Ratio59.21
Debt to Market Cap0.00
Net Debt to EBITDA4.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Janux Therapeutics Inc has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Janux Therapeutics Inc EV to EBITDA ratio is -25.52, with an EV/FCF ratio of -55.92.
EV to Sales233.31
EV to EBITDA-25.52
EV to Free Cash Flow-55.92
EV to Operating Cash Flow-56.38
Balance Sheet
Janux Therapeutics Inc has $988.99M in cash and marketable securities with $22.66M in debt, giving a net cash position of $966.33M billion.
Cash & Marketable Securities$988.99M
Total Debt$22.66M
Net Cash$966.33M
Net Cash Per Share$16.07
Tangible Book Value Per Share$19.03
Margins
Gross margin is -713.04%, with operating margin of -933.58%, and net profit margin of -651.62%.
Gross Margin-713.04%
Operating Margin-933.58%
Pretax Margin-651.62%
Net Profit Margin-651.62%
EBITDA Margin-914.12%
EBIT Margin-933.58%
Analyst Forecast
The average price target for Janux Therapeutics Inc is $75.42, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$75.42
Price Target Upside117.41% Upside
Analyst ConsensusStrong Buy
Analyst Count15
Revenue Growth Forecast-23.37%
EPS Growth Forecast-42.45%